Home/X4 Pharmaceuticals/Gary J. Bridger, PhD

GJ

Gary J. Bridger, PhD

Board of Directors

X4 Pharmaceuticals

Therapeutic Areas

Rare Diseases Immunology Hematology

X4 Pharmaceuticals Pipeline

Drug	Indication	Phase
XOLREMDI® (mavorixafor)	WHIM syndrome (patients 12 years and older)	Approved
Mavorixafor	Chronic Neutropenic Disorders	Phase 3

Leadership Team at X4 Pharmaceuticals

Adam Craig, MD, PhD, MBA

Executive Chair

President, Chief Operating Officer

Chief Financial Officer

View full X4 Pharmaceuticals profile